The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ENVB | -93.66% | -99.99% | -83.13% | -100% |
| S&P | +19.61% | +98.99% | +14.75% | +82% |
Enveric Biosciences, Inc. develops cannabinoid medicines and combination therapies. It is a patient-centric biotechnology company endeavouring to enhance the lives of those who are adversely affected by the side effects of Cancer Treatments. The firm is testing natural compounds, starting with cannabinoids to provide patients and clinicians with novel prescription medicines to serve these unmet medical needs. The company is headquartered in Naples, FL.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.04M | 52.8% |
| Market Cap | $3.66M | -19.8% |
| Market Cap / Employee | $0.73M | 0.0% |
| Employees | 5 | -28.6% |
| Net Income | -$2.52M | -34.0% |
| EBITDA | -$2.48M | -36.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $2.85M | -18.6% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $0.00M | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -207.14% | -73.5% |
| Return On Invested Capital | -321.16% | -146.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1.89M | 34.6% |
| Operating Free Cash Flow | -$1.89M | 34.6% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.08 | 2.29 | 0.88 | 1.68 | 137.82% |
| Price to Tangible Book Value | 127.32 | 150.07 | 7.29 | 9.16 | -92.97% |
| Enterprise Value to EBITDA | -0.51 | -0.41 | 0.85 | -0.12 | -82.96% |
| Return on Equity | -308.6% | -356.8% | -178.9% | -262.0% | 27.10% |
| Total Debt | $0.00M | $0.00M | $0.00M | $0.00M | - |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
